Skip to main content

Main menu

  • Home
  • Content
    • Current
      • JNMT Supplement
    • Ahead of print
    • Past Issues
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNMT
    • Information for Authors
    • Assignment of Copyright
    • AQARA Requirements
  • Info
    • Permissions
    • Continuing Education
    • Advertisers
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNMT
    • JNM
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine Technology
  • SNMMI
    • JNMT
    • JNM
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine Technology

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNMT
    • Information for Authors
    • Assignment of Copyright
    • AQARA Requirements
  • Info
    • Permissions
    • Continuing Education
    • Advertisers
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow SNMMI on Twitter
  • Visit SNMMI on Facebook
  • Join SNMMI on LinkedIn
  • Subscribe to JNMT RSS feeds
NewsVision for the Future

Nuclear Medicine, Molecular Imaging, and Theranostics: The Future Is Bright

Johannes Czernin and Jeremie Calais
Journal of Nuclear Medicine Technology June 2020, 48 (Supplement 1) 82S-83S;
Johannes Czernin
Ahmanson Translational Theranostic Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeremie Calais
Ahmanson Translational Theranostic Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Prospects for nuclear medicine and molecular imaging were bleak in the United States until fairly recently (1). The number of training programs declined, and the professional outlook and career opportunities were dismal for physicians. At the same, time nuclear medicine has been in high demand for many years and is well respected in Europe, Asia, Africa, and Oceania. We have discussed the reasons for this divergent development in detail before (1). Paradoxically, it was probably the great clinical and economic success of PET/CT imaging that led to the decline of our field in the United States. Our community was ill equipped and woefully trained in cross-sectional imaging. Conversely, and at the surface, radiologists had an easy time to adopt PET/CT by simply using FDG as a “contrast” agent. While radiologists had little interest in stand-alone PET operations, they adopted PET/CT imaging, which quickly became a major diagnostic tool in oncology. PET/CT services were provided by free-standing radiology clinics or hospital-based radiology departments.

Figure1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure2
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure3
  • Download figure
  • Open in new tab
  • Download powerpoint

Technologists adapted to these changes as many became certified in CT in addition to nuclear medicine. In Europe, many Asian countries, and Oceana where nuclear medicine training for physicians is far superior, things developed differently. Nuclear medicine became stronger and PET/CT remained its key technology provided by independent nuclear medicine centers.

Molecular imaging kept nuclear medicine relevant. New SPECT and PET imaging probes for cardiac, neurologic, and oncologic indications required special competence provided by our field. Nuclear cardiology remained important, but in the United States cardiology groups provided most of the services.

More recently the tide has turned. Multiple nuclear theranostic approaches have become clinical reality. In addition to the well-established radioablative treatments using 131I for benign and malignant thyroid disease, we now provide 223Ra for patients with bone metastatic disease for palliation but also for survival benefit. Azedra, targeting the norepinephrine transporter, has recently been approved by the Food and Drug Administration as a treatment for pheochromocytoma and paraganglioma (2). Last but not least, 177Lu-DOTATATE, under the trade name Lutathera (Advanced Accelerator Applications), has become a critically important component of managing Neuroendocrine tumors by targeting somatostatin receptors (3).

The greatest excitement stems from targeting the prostate-specific membrane antigen (PSMA) for diagnosis and therapy. Diagnostic studies have shown superior detection rates when compared with fluciclovine (Axumin) in patients with biochemical prostate cancer recurrence (4). Others have demonstrated high impact on managing patients at initial staging and biochemical recurrence and in those with advanced disease (5).

PSMA ligands have been labeled with 177Lu, 131I, and 225Ac for treating patients with late-stage, castrate-resistant prostate cancer. A prospective phase 2 clinical trial showed significant reductions in serum prostate-specific antigen levels in >50% of patients in response to treatment in a population with advanced disease (6). 225Ac appears to be even more effective in this setting, yet is associated with significant salivary gland toxicity. We are convinced that PSMA-targeted therapies will find their way into the clinic and will have significant positive impact on patient outcomes.

The recent advances in diagnostics and therapeutics demand changes in technologist and physician competence. If we do not adapt, others will. Our new service lines are powerful and effective. They will be provided by someone. Let’s keep them in our hands and under our control. Technologists have adapted by becoming dual x ray– and nuclear medicine–certified. This opened up new career opportunities.

Using conservative estimates, we will need more than 100 theranostics clinics that can treat more than 1,000 patients per year (1). We thus need integration with nursing and close collaboration with other clinical disciplines including medical oncology, urology, radiation oncology, endocrinology, and radiology. We need to be informed and knowledgeable about the management of those diseases to which our treatments can contribute. We should serve as treating physicians and consultants to place our therapies in the appropriate clinical context. Technologists, as the first-line contact, and physicians need to work in tandem to inform our patients from first encounter to diagnostic report or therapy administration about the purpose of tests, procedures, and treatments. In other words, our training, knowledge, and competence need to match the high relevance of the services that we can offer.

It has been a long time since our diagnostic and therapeutic service spectrum has created so much excitement. Let’s make sure to make the best of this opportunity for our patients but also for our field.

REFERENCES

  1. 1.↵
    1. Czernin J,
    2. Sonni I,
    3. Razmaria A,
    4. Calais J
    . The future of nuclear medicine as an independent specialty. J Nucl Med. 2019;60(suppl 2):3S–12S.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Pryma DA,
    2. Chin BB,
    3. Noto RB,
    4. et al.
    Efficacy and safety of high-specific-activity 131I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma. J Nucl Med. 2019;60:623–630.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Hope TA,
    2. Bodei L,
    3. Chan JA,
    4. et al.
    NANETS/SNMMI consensus statement on patient selection and appropriate use of 177Lu-DOTATATE peptide receptor radionuclide therapy. J Nucl Med. 2020;61:222–227.
    OpenUrlFREE Full Text
  4. 4.↵
    1. Calais J,
    2. Ceci F,
    3. Eiber M,
    4. et al.
    18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol. 2019;20:1286–1294.
    OpenUrl
  5. 5.↵
    Sonni I, Eiber M, Fendler WP, et al. Impact of 68Ga-PSMA-11 PET/CT on staging and management of prostate cancer patients in various clinical settings: a prospective single center study. J Nucl Med. January 10, 2020 [Epub ahead of print].
  6. 6.↵
    1. Violet J,
    2. Sandhu S,
    3. Iravani A,
    4. et al.
    Long term follow-up and outcomes of re-treatment in an expanded 50 patient single-center phase II prospective trial of Lutetium-177 (177Lu) PSMA-617 theranostics in metastatic castrate-resistant prostate cancer. J Nucl Med. November 15, 2019 [Epub ahead of print].
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine Technology: 48 (Supplement 1)
Journal of Nuclear Medicine Technology
Vol. 48, Issue Supplement 1
June 1, 2020
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine Technology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Nuclear Medicine, Molecular Imaging, and Theranostics: The Future Is Bright
(Your Name) has sent you a message from Journal of Nuclear Medicine Technology
(Your Name) thought you would like to see the Journal of Nuclear Medicine Technology web site.
Citation Tools
Nuclear Medicine, Molecular Imaging, and Theranostics: The Future Is Bright
Johannes Czernin, Jeremie Calais
Journal of Nuclear Medicine Technology Jun 2020, 48 (Supplement 1) 82S-83S;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Nuclear Medicine, Molecular Imaging, and Theranostics: The Future Is Bright
Johannes Czernin, Jeremie Calais
Journal of Nuclear Medicine Technology Jun 2020, 48 (Supplement 1) 82S-83S;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • The Future of Health Care and the Importance of the Nuclear Medicine Technologist
Show more Vision for the Future

Similar Articles

SNMMI

© 2023 Journal of Nuclear Medicine Technology

Powered by HighWire